Medical Educational Resource
Recent Developments in the Spinal Muscular Atrophy Treatment Landscape
This program is supported in part by an independent medical education grant from AveXis Inc.
This webinar will help physicians learn about rapidly changing treatment options in SMA and facilitate the integration of new treatments into the comprehensive management of patients with SMA. MDA invites clinicians in our community to use this resource to educate themselves and other providers, while earning CME credits.
- Explain the importance of a timely, accurate SMA diagnosis and why early intervention is crucial
- Compare and contrast the different therapies on the market or in clinical development, their administration, and the appropriate patient populations for each
- Identify and recognize additional disease phenotypes that may manifest over the course of the disease
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute, LLC and Muscular Dystrophy Association. The PeerPoint Medical Education Institute, LLC is accredited by the ACCME to provide continuing medical education for physicians.
The PeerPoint Medical Education Institute, LLC designates this Enduring Material activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Once you have viewed the program, MDA will share back with you instructions for how to obtain your CME credits. If you have questions on this process, please reach out to firstname.lastname@example.org.
The following presenters, planners, editors, or staff have relevant financial relationships to disclose:
"I, or an immediate family member, have at present or have had within the last 12 months, the following affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation, evaluation, etc. of CME Activities."
Dr. Julie Parsons:
Biogen: Advisory Board, Principal Investigator; consulting fee, research support
AveXis: Advisory Board, Principal Investigator; consulting fee, research support
Scholar Rock: Principal Investigator; research support
Dr. Claudia Chiriboga:
AveXis: Consultant; consulting fee
Roche/Genentec: Consultant; consulting fee
Biogen: Educational speaker; honoraria
All other presenters, planners, editors, or staff reported no relevant relationships with the following statement:
"I, or an immediate family member, do not have at present, or within the last 12 months, nor anticipate having financial interest, arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation, evaluation, etc. of CME Activities."
Copyright 2021 Muscular Dystrophy Association. All rights reserved. The Medical Education Program(s) in their entirety (including, but not limited to: webinar(s), speaker deck presentation(s), MDA Monthly Report content and case studies) are owned by Muscular Dystrophy Association and the associated partner(s) and may not be copied, reproduced, or altered in any manner without MDA’s prior written consent except that the User(s) may download, view, or use these program(s) for educational purposes only.
If you wish to alter any of the Medical Education Program(s) presented by the MDA in a form other than what is set out on mda.org, please consult email@example.com.